New trial aims to save rectums in rectal cancer patients

NCT ID NCT06952101

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a personalized, stage-based approach to treat rectal cancer while trying to avoid removing the rectum. 200 participants will receive either experimental chemoradiotherapy or minimally invasive surgery depending on their cancer stage. The goal is to preserve the rectum and improve quality of life without compromising cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
chemoradiotherapy (experimental and standard), minimally invasive surgery (laparoscopic/robotic)
What this could lead to
If successful, this could offer a way to treat rectal cancer without removing the rectum, preserving bowel function and quality of life for many patients.
What could go wrong
This is an early-phase study with only 200 participants, so results may not apply to everyone. The organ-sparing approach may not work for all patients, and some may still need surgery or face cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Surgical Oncology - FPO-IRCCS Institute for Cancer Research and Treatment

    RECRUITING

    Candiolo, Turin, 10060, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.